June 19, 2023
Takeda Pharmaceutical said on June 15 that the European Medicines Agency (EMA) has accepted for review a regulatory application for fruquintinib, licensed from China ally Hutchmed, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). The...read more